Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins

Metabolism: Clinical and Experimental

Volumn 57, Issue 8, 2008, Pages 1088-1092

  Vrablik, Michal ^a   Fait, Tomas ^a   Kovar, Jan ^b   Poledne, Rudolf ^b   Ceska, Richard ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CLIMARA EMPLASTRUM; ESTRADIOL; ESTROFEM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; HYSTERECTOMY; LIPID BLOOD LEVEL; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STUDENT T TEST; ULTRACENTRIFUGATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYSTERECTOMY; LIPOPROTEINS; MIDDLE AGED; OVARIECTOMY; TRIGLYCERIDES;

EID: 47149108557     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.03.012     Document Type: Article

References (47)

1. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
2. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
3. Fait T., Vokrouhlicka J., Vrablik M., et al. Present position of the hormonal replacement therapy. Cas Lek Cesk 143 (2004) 447-452
4. Fait T., Vrablik M., Cibula D., et al. Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study. Neuro Endocrinol Lett 27 (2006) 665-668
5. Koh K.K., and Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials?. Arterioscler Thromb Vasc Biol 24 (2004) 1171-1179
6. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 15 (2006) 35-44
7. Austin M.A., Hokanson J.E., and Brunzell J.D. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 5 (1994) 395-403
8. Austin M.A., Breslow J.L., Hennekens G.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
9. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 31 (2005) 429-439
10. Nesto R.W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5 (2005) 379-387
11. Wakatsuki A., Okatani Y., Ikenoue N., et al. Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 108 (2003) 808-813
12. Wakatsuki A., Ikenoue N., Okatani Y., et al. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol 37 (2001) 425-430
13. Balci H., Altunyurt S., Acar B., et al. Effects of transdermal estrogen replacement therapy on plasma levels of nitric oxide and plasma lipids in postmenopausal women. Maturitas 50 (2005) 289-293
14. Lahdenpera S., Puolakka J., Pyorala T., et al. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. Atherosclerosis 122 (1996) 153-162
15. Wakatsuki A., Okatani Y., Ikenoue N., et al. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 106 (2002) 1771-1776
16. Godsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 75 (2001) 898-915
17. Lobo R.A., Pickar J.H., Wild R.A., et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 84 (1994) 987-995
18. Odmark I.S., Backstrom T., Haeger M., et al. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. Maturitas 48 (2004) 137-146
19. Walsh B.H., Li H., and Sacks F.M. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high-density lipoprotein metabolism. J Lipid Res 35 (1994) 2083-2093
20. Tangney C.C., Mosca L.J., Otvos J.D., et al. Oral 17beta-estradiol and medroxyprogesterone acetate therapy in postmenopausal women increases HDL particle size. Atherosclerosis 155 (2001) 425-430
21. Crook D., Cust M.P., Gangar K.F., et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 166 (1992) 950-955
22. Whitehead M.I., Fraser D., Schenkel L., et al. Transdermal administration of oestrogen/progestagen hormone replacement therapy. Lancet 335 (1990) 310-312
23. Karim R., Mack W.J., Lobo R.A., et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. Menopause 12 (2005) 366-373
24. Dobiášová M., and Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 34 (2001) 583-588
25. Dobiášová M. Atherogenic index of plasma [log(triglycerides/HDL cholesterol)]: theoretical and practical implications. Clin Chem 50 (2004) 113-115
26. Frohlich J., and Dobiášová M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 49 (2003) 1873-1880
27. Brown B.G., Xue-Qiao Z., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
28. Rees M., and Purdie D.W. Management of the menopause (2006), Royal Society of Medicine Press, London 170
29. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
30. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379
31. Chapman M.J., Guerin M., and Bruckert E. Atherogenic, low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 19 (1998) A24-A30
32. Austin M.A., Mykkanen L., Kuusisto J., et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92 (1995) 1770-1778
33. Bjornheded T., Babyi A., Bodjers G., et al. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123 (1996) 43-56
34. Coresh J., Kwiterowich P.O., Smith H.H., et al. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34 (1993) 1687-1697
35. Gardner C.D., Fortmann S.P., and Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276 (1996) 875-881
36. Packard C.M., Caslake M., and Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 74 (2000) S17-S22
37. Skeggs J.W., and Morton R.E. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport. J Lipid Res 43 (2002) 1264-1274
38. Tilly-Kiesi M., Kahri J., Pyorala T., et al. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. Atherosclerosis 129 (1997) 249-259
39. Patsch J.R., Prasad S., Gotto Jr. A.M., et al. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 80 (1987) 341-347
40. Patsch J.R., Prasad S., Gotto Jr. A.M., et al. Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. J Clin Invest 74 (1984) 2017-2023
41. Lamarche B., Uffelman K.D., Carpentier A., et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 103 (1999) 1191-1199
42. Rashid S., Barrett P.H., Uffelman K.D., et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol 22 (2002) 483-487
43. Cheung M.C., Sibley S.D., Palmer J.P., et al. Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II). J Lipid Res 44 (2003) 1552-1558
44. Jones D.R., Schmidt R.J., Pickard R.T., et al. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res 43 (2002) 383-391
45. Murdoch S.J., and Breckenridge W.C. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis 118 (1995) 193-212
46. Colvin P.L., Auerbach B.J., Case L.D., et al. A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism 40 (1991) 1052-1056
47. Tan M.H., Johns D., and Glazer N.B. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 50 (2004) 1184-1188